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See Article, pages 1391–1399Body epithelial surfaces, such as the airways, the skin, the mouth,
and the lower gastrointestinal tract provide residence to a num-
ber of microbes that by far exceeds the number of cells of human
beings. These microbial populations not only contribute to the
process of development of their host and maintain tissue homeo-
stasis, but also play a critical role in governing important physi-
ological processes like for instance the absorption of vitamins
and nutrients from the intestinal lumen [1]. Under normal condi-
tions, the barrier function of the intestinal mucosa prevents bac-
teria from translocating through the gut epithelium into the
portal and systemic circulation. The permeability of the intestinal
wall is maintained thanks to three main mechanisms. First, intra-
luminal bacteria are prevented from growing excessively by the
peristaltic activity of the muscular layers and by the action of
antimicrobial peptides and defensins. Second, tight junctions,
an intact epithelial layer, and mucus represent the main physical
barriers to the passage of bacteria. Finally, cellular components of
the gut-associated lymphoid tissue (dendritic cells, macrophages,
lymphocytes) provide the third line of defence by eliminating any
bacteria that is able to penetrate through the epithelial barrier
[2–4].
The impact of the intestinal bacterial ﬂora on host physiology
is not limited to the digestive tube. For example, interactions
between the immune system and gut bacteria can signiﬁcantly
affect the energetic balance of the host by altering the absorption
of sugars, by modifying the degree of insulin resistance or by
modulating inﬂammatory signalling [5,6]. Emerging evidence
shows that systemic pathological conditions, such as obesity,
may be inﬂuenced by the microbiota in the gut [7]. Lifestyle
changes characterized by an increased caloric intake, high fat
diets, and sedentary habits may result in an altered composition
of the intestinal ﬂora called dysbiosis that ends in an imbalance
between tolerogenic and inﬂammatory members of the microbi-
ota. In addition, recent data demonstrate that gut-ﬂora-formed
trimethylamine (TMA) from dietary choline acts as a proathero-
genic compound after its conversion into TMA N-oxide in theJournal of Hepatology 20
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Open access under CC BY-NC-ND license.liver, suggesting a direct link between intestinal microﬂora and
risk of cardiovascular disease [8].
The current increasing incidence of non-alcoholic fatty liver
disease (NAFLD) in the general population is a consequence of
the growing burden of the metabolic syndrome [9]. Importantly,
while simple steatosis seems to be very well tolerated and to
have only mild consequences, a signiﬁcant proportion of patients
with NAFLD develop non-alcoholic steatohepatitis, a condition
that may result in hepatic ﬁbrosis [10], cirrhosis, and hepatocel-
lular carcinoma [11]. Although the circumstances that may lead
to liver ﬁbrosis have been broadly related to insulin resistance
and pro-inﬂammatory conditions, the precise mechanisms and
the cofactors that aggravate ﬁbrogenesis remain largely
unknown. The hypothesis that components from the intestinal
microﬂora may contribute to the regulation of pro-ﬁbrogenic
and inﬂammatory processes in the liver has been investigated
in recent years [12] and it has become clear that this area will
need extensive investigation in the near future. In both animal
models [13] and humans [14], an increased systemic concentra-
tion of bacterial lipopolysaccharide (LPS), a component of the cell
wall from Gram negative bacteria, has been demonstrated in
obese subjects compared to lean controls as well as in patients
with NAFLD (for a comprehensive review see reference [6]).
These data suggest that intestinal bacteria may play a role in
the development of obesity and metabolic syndrome.
Commensal and pathogenic microbes share similar molecular
structures, such as lipopolysaccharide, lipoproteins, ﬂagellins,
and peptidoglycans. The recognition of speciﬁc signature mole-
cules termed pathogen-associated molecular patterns (PAMPs)
by toll-like receptors (TLRs) is the basis of the innate immune
system, which represents the ﬁrst line defense against invading
pathogens [15]. TLR4 is the main receptor for LPS while other
TLRs recognize microorganism-derived ligands like ﬂagellins or
nucleic acids. Metabolic systems are closely integrated with
downstream signals of TLR. When pathogens are sensed by the
innate immune system, insulin signalling, and inﬂammatory
pathways are modulated as a consequence of the interaction
between signals that control immunologic and metabolic pro-
cesses [16,17]. Obesity and insulin resistance are associated with
an increased expression of pro-inﬂammatory and proﬁbrogenic
cytokines [10]: this observation opens the question on whether11 vol. 55 j 1181–1183
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Fig. 1. Schematic representation of the experimental model used to induce NASH (high fat diet) and enhance intestinal permeability (dextran sulfate sodium, DSS)
in rats. The article by Gäbele et al. is an additional contribution to the areas of investigation represented in squares. GALT: gut-associated lymphoid tissue. PAMPs:
pathogen-associated molecular patterns.
Editorialintestinal bacteria may act as co-regulators in inﬂammatory and
metabolic mechanisms.
In this issue of the Journal of Hepatology, Gäbele and
co-authors present novel experimental evidence about the asso-
ciation between impaired intestinal immunity and hepatic ﬁbro-
genesis and inﬂammation. The authors induced a mild form of
non-alcoholic steatohepatitis by feeding C57BL/6 mice with a
high-fat diet and then studied the effects of exposing the mice
to 1% dextran sulfate sodium (DSS) in the drinking water. DSS
exposure leads to epithelial injury, which induces inﬂammation
and colitis. They observed that the combined administration of
a high-fat diet and DSS not only aggravated steatohepatitis, but
also induced a pro-ﬁbrogenic response in the liver (Fig. 1). The
partial impairment of the barrier function of the intestinal
mucosa was assessed by the quantiﬁcation of LPS levels in the
portal vein. Interestingly, the production of pro-inﬂammatory
cytokines in the mesenteric lymph nodes was not enhanced in
any group. In contrast, the authors observed a decrease in the
antimicrobial peptide Cramp in mice treated with both high-fat
diet and DSS compared to mice treated with DSS alone, suggest-
ing that the hepatic pro-inﬂammatory response may be a conse-
quence of both the intestinal barrier deﬁcit as well as an1182 Journal of Hepatology 2011impairment of local antimicrobial mechanisms. In addition, the
hepatic expression of TLR4 and TLR9 and markers of oxidative
stress were signiﬁcantly increased following the combined
treatment of a high-fat diet and DSS and this was associated with
augmented markers of ﬁbrosis.
The work by Gäbele and coauthors provides novel and
interesting insights into the pathophysiology of non-alcoholic
fatty liver disease. Further studies investigating the effects of
modulating the composition of the intestinal ﬂora by pre-,
pro- or antibiotics on the development of inﬂammation and
ﬁbrosis in this animal model will be informative. In addition,
translational studies to investigate the availability of such
treatments for clinical use would certainly be welcome. Fur-
thermore, additional knowledge on the composition and the
effects of single bacterial strains (commensals or not) may con-
tribute to a better understanding of the interactions between
intestinal ﬂora and host in NAFLD and metabolic disorders. In
this regard, a recent study demonstrates the existence of three
different major clusters of gut bacteria (referred to as entero-
types) in humans, suggesting that well-deﬁned host-microbial
symbiotic states might determine different responses to diet
and drug intake [18].vol. 55 j 1181–1183
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Most importantly however, while the ﬁndings of this study
provide new interesting information, they also generate a num-
ber of additional important questions concerning the role of the
microbial ﬂora and the mechanisms regulating the expression
of intestinal antimicrobial peptides in the gut-liver axis that
should be addressed in future investigations.Conﬂict of interest
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